TG Therapeutics: The 'Exit Velocity' You Can't Ignore (Rating Upgrade) [Seeking Alpha]
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: Seeking Alpha
TGTX guides for 2026 BRIUMVI U.S. net revenue of $825–$850 million, implying ~40% YoY growth and continued base expansion beyond Q4 2025 run rate. Strategic low pricing, administrative simplification, and subcutaneous formulation development underpin TGTX's competitive positioning and future margin expansion. My DCF model suggests TGTX is undervalued by ~21%, with blockbuster BRIUMVI performance and subcutaneous readiness driving a favorable risk/reward profile. anyaberkut/iStock via Getty Images My last article on TG Therapeutics, Inc. ( TGTX ) followed its first quarter 2025 earnings report, in which BRIUMVI contributed nearly $120 million, which represented a 130% increase year-over-year. As I've expressed in the past, however, TG was pretty slow to This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote th
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics (NASDAQ:TGTX) was given a new $39.00 price target on by analysts at The Goldman Sachs Group, Inc.. They now have a "neutral" rating on the stock.MarketBeat
- TG Therapeutics (NASDAQ:TGTX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development MilestonesGlobeNewswire
- TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
TGTX
Earnings
- 11/3/25 - Beat
TGTX
Sec Filings
- 1/13/26 - Form 8-K
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- TGTX's page on the SEC website